| Literature DB >> 24162035 |
Susanne Hansen1, Marin Strøm, Sjurdur F Olsen, Ekaterina Maslova, Panu Rantakokko, Hannu Kiviranta, Dorte Rytter, Bodil H Bech, Linda V Hansen, Thorhallur I Halldorsson.
Abstract
BACKGROUND: Previous findings suggest that developmental exposures to persistent organochlorine pollutants (POPs) may be detrimental for the development of the immune system in the offspring. Whether these suspected immunoregulatory effects persist beyond early childhood remains unclear.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24162035 PMCID: PMC3888563 DOI: 10.1289/ehp.1206397
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Maternal and offspring characteristics of 872 mother–child pairs.
| Characteristic | Median (10th, 90th percentiles), mean ± SD, or |
|---|---|
| Maternal | |
| Serum concentration (ng/mL) | |
| PCB-118 | 0.17 (0.09, 0.30) |
| PCB-138 | 0.74 (0.41, 1.25) |
| PCB-153 | 1.37 (0.76, 2.26) |
| PCB-156 | 0.10 (0.06, 0.16) |
| PCB-170 | 0.37 (0.21, 0.59) |
| PCB-180 | 0.67 (0.38, 1.10) |
| Sum of PCBs (pmol/mL) | 9.23 (5.32, 15.11) |
| HCB | 0.54 (0.31, 0.87) |
| 2.47 (1.03, 5.66) | |
| Maternal age at birth (years) | 29.0 ± 4.2 |
| Fish intake (g/day) | 19.3 ± 15.6 |
| Alcohol (g/day) | 2.9 ± 3.8 |
| Maternal cholesterol (mmol/L) | 7.3 ± 1.3 |
| Maternal triglycerides (mmol/L) | 2.4 ± 0.8 |
| Previous births | |
| 0 | 500 (57.3) |
| 1 | 279 (32.0) |
| ≥ 2 | 93 (10.7) |
| Cigarettes/day during pregnancy | |
| 0 | 493 (56.5) |
| > 0–5 | 99 (11.4) |
| > 5 to 15 | 188 (21.6) |
| > 15 | 41 (4.7) |
| Missing | 51 (5.9) |
| Maternal education | |
| Elementary school | 103 (11.8) |
| High school or technical school | 207 (23.7) |
| University | 296 (33.9) |
| Higher academic | 125 (14.3) |
| Other education | 89 (10.2) |
| Missing | 52 (6.0) |
| Prepregnancy BMI (kg/m2) | |
| < 18.5 | 89 (10.2) |
| 18.5 to < 25 | 676 (77.5) |
| 25 to < 30 | 53 (6.1) |
| > 30 | 23 (2.6) |
| Missing | 31 (3.6) |
| Offspring | |
| Registry-based diagnoses ( | |
| Asthma medication | 111 (12.7) |
| Asthma hospitalization | 32 (3.7) |
| Self-reported diagnoses ( | |
| Lifetime doctor diagnosis | 89 (13.6) |
| Current asthma medication use | 48 (7.3) |
| Birth weight (g) | 3493.7 ± 579.9 |
| Gestational age (days) | 282.3 ± 11.8 |
| Boys | 461 (52.9) |
| Age at follow-up (years) | 19.6 ± 0.49 |
Maternal and offspring characteristics of 872 mother–child pairs across tertiles of maternal PCB, HCB, and p,p´-DDE serum concentrations.
| Characteristic | 1st tertile | 2nd tertile | 3rd tertile | |
|---|---|---|---|---|
| Values are mean ± SD, | ||||
| PCB concentration (pmol/mL) (range) | 1.4–7.7 | 7.7–11.1 | 11.1–80.6 | |
| Maternal | ||||
| Maternal age at birth (years) | 27.6 ± 4.1 | 29.1 ± 3.9 | 30.4 ± 4.2 | < 0.001 |
| Fish intake (g/day) | 18.8 ± 16.3 | 18.4 ± 13.4 | 20.6 ± 16.7 | 0.21 |
| Alcohol (g/day) | 2.5 ± 3.7 | 2.9 ± 3.3 | 3.4 ± 4.2 | 0.01 |
| Previous births (% nulliparous) | 152 (52.4) | 160 (55.0) | 188 (64.6) | 0.02 |
| Smoking during pregnancy (% no) | 157 (57.5) | 182 (66.4) | 154 (56.2) | 0.09 |
| Maternal education (% higher academic) | 37 (13.6) | 42 (15.4) | 46 (16.8) | 0.02 |
| Prepregnancy BMI (kg/m2) | 21.5 ± 3.0 | 21.5 ± 3.1 | 21.3 ± 3.2 | 0.72 |
| Offspring | ||||
| Birth weight (g) | 3514.8 ± 507.7 | 3503.3 ± 563.8 | 3462.7 ± 541.1 | 0.47 |
| Gestational age (days) | 283 ± 10.8 | 283 ± 12.2 | 281 ± 12.3 | 0.03 |
| Sex (% boys) | 142 (49.0) | 150 (51.6) | 169 (58.1) | 0.08 |
| Asthma medication ( | 33 | 36 | 42 | 0.53 |
| Asthma hospital diagnoses ( | 8 | 12 | 12 | 0.60 |
| Self-reported diagnoses ( | 22 | 34 | 33 | 0.26 |
| Current self-reported medication use ( | 11 | 18 | 19 | 0.35 |
| HCB concentrations (ng/mL) (range) | 0.1–0.5 | 0.5–0.6 | 0.6–2.5 | |
| Maternal | ||||
| Maternal age at birth (years) | 28.0 ± 4.1 | 28.9 ± 3.8 | 30.2 ± 4.2 | < 0.001 |
| Fish intake (g/day) | 18.1 ± 14.5 | 19.5 ± 15.7 | 20.2 ± 16.3 | 0.24 |
| Alcohol (g/day) | 2.6 ± 3.8 | 3.0 ± 3.5 | 3.2 ± 3.9 | 0.14 |
| Previous births (% nulliparous) | 140 (48.3) | 168 (57.7) | 192 (66.0) | < 0.001 |
| Smoking during pregnancy (% no) | 162 (59.6) | 162 (59.3) | 169 (61.2) | 0.64 |
| Maternal education (% higher academic) | 36 (13.2) | 44 (16.2) | 45 (16.3) | 0.22 |
| Prepregnancy BMI (kg/m2) | 21.0 ± 2.5 | 21.2 ± 2.4 | 22.1 ± 4.0 | < 0.001 |
| Offspring | ||||
| Birth weight (g) | 3483.2 ± 503.1 | 3534.7 ± 534.8 | 3463.0 ± 572.8 | 0.25 |
| Gestational age (days) | 283 ± 11.7 | 283 ± 10.9 | 281 ± 12.8 | 0.04 |
| Sex (% boys) | 147 (50.7) | 155 (53.3) | 159 (54.6) | 0.63 |
| Asthma medication ( | 28 | 35 | 48 | 0.04 |
| Asthma hospital diagnoses ( | 8 | 12 | 12 | 0.60 |
| Self-reported diagnoses ( | 20 | 34 | 35 | 0.07 |
| Current self-reported medication use ( | 6 | 20 | 22 | 0.01 |
| 0.2–1.9 | 1.9–3.2 | 3.3–38.8 | ||
| Maternal | ||||
| Maternal age at birth (years) | 28.0 ± 4.2 | 28.8 ± 4.0 | 30.3 ± 4.1 | < 0.001 |
| Fish intake (g/day) | 19.1 ± 14.7 | 17.7 ± 14.4 | 20.9 ± 17.3 | 0.05 |
| Alcohol (g/day) | 2.4 ± 3.2 | 3.1 ± 3.9 | 3.4 ± 4.1 | 0.01 |
| Previous births (% nulliparous) | 148 (51.0) | 171 (58.8) | 181 (62.2) | 0.05 |
| Smoking during pregnancy (% no) | 162 (58.5) | 174 (64.4) | 157 (57.3) | 0.59 |
| Maternal education (% higher academic) | 35 (12.6) | 38 (14.1) | 52 (19.0) | 0.03 |
| Prepregnancy BMI (kg/m2) | 20.9 ± 2.7 | 21.5 ± 2.9 | 21.8 ± 3.6 | 0.003 |
| Offspring | ||||
| Birth weight (g) | 3499.9 ± 533.5 | 3494.7 ± 519.8 | 3486.6 ± 561.1 | 0.96 |
| Gestational age (days) | 283 ± 11.7 | 282 ± 11.8 | 282 ± 12.0 | 0.49 |
| Sex (% boys) | 146 (50.3) | 159 (54.6) | 156 (53.6) | 0.56 |
| Asthma medication ( | 37 | 34 | 40 | 0.76 |
| Asthma hospital diagnoses ( | 10 | 11 | 11 | 0.97 |
| Self-reported diagnoses ( | 30 | 31 | 28 | 0.89 |
| Current self-reported medication use ( | 16 | 16 | 16 | 0.99 |
Associations between maternal PCBs, HCB, and p,p´-DDE serum concentrations and offspring asthma medication use after 20 years of follow-up (n = 872) [HR (95% CI)].
| POPs in tertiles (range) | Raw model | Adjusted model |
|---|---|---|
| PCB–118 (ng/mL) | ||
| 1st (0.02–0.14) | 1.00 | 1.00 |
| 2nd (> 0.14–0.20) | 1.50 (0.92, 2.45) | 1.60 (0.96, 2.66) |
| 3rd (> 0.20–0.61) | 1.69 (1.05, 2.73) | 1.90 (1.12, 3.23) |
| 0.04 | 0.02 | |
| PCB–156 (ng/mL) | ||
| 1st (0.01–0.08) | 1.00 | 1.00 |
| 2nd (> 0.08–0.12) | 1.33 (0.82, 2.15) | 1.38 (0.84, 2.26) |
| 3rd (> 0.12–0.92) | 1.43 (0.90, 2.29) | 1.45 (0.85, 2.46) |
| 0.15 | 0.20 | |
| Dioxin-like PCBs (pmol/mL) | ||
| 1st (0.13–0.67) | 1.00 | 1.00 |
| 2nd (> 0.67–0.96) | 1.45 (0.90, 2.35) | 1.56 (0.95, 2.56) |
| 3rd (> 0.96–4.10) | 1.59 (0.99, 2.55) | 1.75 (1.02, 2.98) |
| 0.07 | 0.05 | |
| Non-dioxin-like PCBs (pmol/mL) | ||
| 1st (1.23–7.09) | 1.00 | 1.00 |
| 2nd (> 7.10–10.12) | 1.10 (0.69, 1.77) | 1.15 (0.70, 1.86) |
| 3rd (> 10.12–76.55) | 1.30 (0.83, 2.06) | 1.30 (0.78, 2.17) |
| 0.24 | 0.32 | |
| Sum of all PCBs (pmol/mL) | ||
| 1st (1.43–7.72) | 1.00 | 1.00 |
| 2nd (> 7.73–11.11) | 1.10 (0.68, 1.76) | 1.15 (0.70, 1.87) |
| 3rd (> 11.11–80.65) | 1.30 (0.83, 2.06) | 1.30 (0.78, 2.17) |
| 0.24 | 0.32 | |
| HCB (ng/mL) | ||
| 1st (0.07–0.45) | 1.00 | 1.00 |
| 2nd (> 0.45–0.63) | 1.26 (0.77, 2.07) | 1.31 (0.79, 2.17) |
| 3rd (> 0.63–2.45) | 1.78 (1.12, 2.84) | 1.92 (1.15, 3.21) |
| 0.01 | 0.01 | |
| 1st (0.20–1.86) | 1.00 | 1.00 |
| 2nd (> 1.86–3.24) | 0.91 (0.57, 1.44) | 0.92 (0.5, 1.47) |
| 3rd (> 3.25–38.77) | 1.09 (0.70, 1.71) | 1.09 (0.67, 1.77) |
| 0.62 | 0.64 | |
Associations between maternal PCBs, HCB, and p,p´-DDE serum concentrations and the risk of offspring hospital diagnoses (n = 872), self-reported doctor diagnosis of asthma (n = 654), and self-reported current medication use (n = 654) in the adjusted model.
| POPs in tertiles (range) | Asthma hospital diagnoses [HR | Self-reported lifetime diagnosis [Odds ratio | Current self-reported medication use [Odds ratio |
|---|---|---|---|
| PCB-118 (ng/mL) | |||
| 1st (0.02–0.14) | 1.00 | 1.00 | 1.00 |
| 2nd (> 0.14–0.20) | 0.85 (0.50, 1.46) | 1.76 (0.94, 3.26) | 1.90 (0.80, 4.52) |
| 3rd (> 0.20–0.61) | 1.31 (0.78, 2.20) | 1.73 (0.90, 3.31) | 2.49 (1.03, 5.99) |
| 0.32 | 0.16 | 0.05 | |
| PCB-156 (ng/mL) | |||
| 1st (0.01–0.08) | 1.00 | 1.00 | 1.00 |
| 2nd (> 0.08–0.12) | 1.38 (0.85, 2.25) | 1.52 (0.83, 2.80) | 1.75 (0.75, 4.07) |
| 3rd (> 0.12–0.92) | 0.94 (0.53, 1.66) | 1.41 (0.73, 2.71) | 2.01 (0.82, 4.93) |
| 0.76 | 0.38 | 0.15 | |
| Dioxin-like PCBs (pmol/mL) | |||
| 1st (0.13–0.67) | 1.00 | 1.00 | 1.00 |
| 2nd (> 0.67–0.96) | 1.36 (0.84, 2.21) | 1.83 (1.00, 3.36) | 1.80 (0.79, 4.11) |
| 3rd (> 0.96–4.10) | 1.00 (0.57, 1.75) | 1.45 (0.75, 2.83) | 1.90 (0.79, 4.59) |
| 0.40 | 0.40 | 0.19 | |
| Non-dioxin-like PCBs (pmol/mL) | |||
| 1st (1.23–7.09) | 1.00 | 1.00 | 1.00 |
| 2nd (> 7.10–10.12) | 1.01 (0.61, 1.68) | 1.40 (0.77, 2.56) | 1.35 (0.60, 3.00) |
| 3rd (> 10.12–76.55) | 1.19 (0.69, 2.04) | 1.27 (0.67, 2.44) | 1.48 (0.63, 3.46) |
| 0.40 | 0.57 | 0.39 | |
| Sum of all PCBs (pmol/mL) | |||
| 1st (1.43–7.72) | 1.00 | 1.00 | 1.00 |
| 2nd (> 7.73–11.11) | 1.12 (0.68, 1.84) | 1.59 (0.87, 2.90) | 1.59 (0.71, 3.60) |
| 3rd (> 11.11–80.65) | 1.22 (0.71, 2.09) | 1.30 (0.67, 2.51) | 1.63 (0.68, 3.88) |
| 0.30 | 0.59 | 0.32 | |
| HCB (ng/mL) | |||
| 1st (0.07–0.45) | 1.00 | 1.00 | 1.00 |
| 2nd (> 0.45–0.63) | 1.66 (0.66, 4.13) | 1.79 (0.97, 3.31) | 3.38 (1.29, 8.85) |
| 3rd (> 0.63–2.45) | 1.84 (0.70, 4.86) | 1.85 (0.97, 3.51) | 4.18 (1.57, 11.15) |
| 0.24 | 0.09 | 0.01 | |
| 1st (0.20–1.86) | 1.00 | 1.00 | 1.00 |
| 2nd (> 1.86–3.24) | 1.17 (0.49, 2.80) | 0.96 (0.55, 1.69) | 0.95 (0.45, 1.98) |
| 3rd (> 3.24–38.77) | 1.14 (0.46, 2.85) | 0.80 (0.44, 1.45) | 0.86 (0.40, 1.85) |
| 0.80 | 0.48 | 0.91 | |